Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NBY

NBY - NovaBay Pharmaceuticals Inc Stock Price, Fair Value and News

$2.02-0.35 (-14.77%)
Market Closed

18/100

NBY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

18/100

NBY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.77

Target 3M

$4.24

Target 6M

$4

NBY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NBY Price Action

Last 7 days

-65.6%

Last 30 days

-58.4%

Last 90 days

71.2%

Trailing 12 Months

197.1%

NBY RSI Chart

NBY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NBY Valuation

Market Cap

254.5M

Price/Earnings (Trailing)

78.49

Price/Sales (Trailing)

33.18

EV/EBITDA

-43.18

Price/Free Cashflow

-46.1

NBY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.77

Target 3M

$4.24

Target 6M

$4

NBY Fundamentals

NBY Revenue

Revenue (TTM)

7.7M

Rev. Growth (Yr)

-78.66%

Rev. Growth (Qtr)

-77.44%

NBY Earnings

Earnings (TTM)

3.2M

Earnings Growth (Yr)

-6.68%

Earnings Growth (Qtr)

32.73%

NBY Profitability

EBT Margin

-179.09%

Return on Equity

292.43%

Return on Assets

93%

Free Cashflow Yield

-2.17%

NBY Investor Care

Shares Dilution (1Y)

2479.18%

Diluted EPS (TTM)

-1.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025007.7M0
202410.7M9.6M9.6M9.8M
202313.5M13.3M12.0M10.5M
202211.3M12.8M14.3M14.4M
20219.8M8.0M8.1M9.8M
20207.0M9.2M9.8M9.9M
201911.1M10.0M8.5M6.6M
201817.5M16.1M15.2M12.5M
201713.9M15.3M16.0M18.2M
20165.6M7.2M9.5M11.9M
20151.4M2.2M3.3M4.4M
20142.7M2.0M1.1M1.0M
20136.6M6.5M4.0M3.5M
20129.8M6.2M7.1M6.9M
201110.2M12.1M12.8M11.0M
2010013.7M11.7M9.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About NovaBay Pharmaceuticals Inc

NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
 CEO
 WEBSITEhttps://novabay.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES29

NovaBay Pharmaceuticals Inc Frequently Asked Questions

NBY is the stock ticker symbol of NovaBay Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of NovaBay Pharmaceuticals Inc is 254.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NBY's fair value in chart for subscribers.

The fair value guage provides a quick view whether NBY is over valued or under valued. Whether NovaBay Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact NovaBay Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBY.

As of Wed Jan 28 2026, NBY's PE ratio (Price to Earnings) is 78.49 and Price to Sales (PS) ratio is 33.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBY PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, NovaBay Pharmaceuticals Inc has provided -0.521 (multiply by 100 for percentage) rate of return.